Differential <i>MUC22</i> expression by epigenetic alterations in human lung squamous cell carcinoma and adenocarcinoma.

ABSTRACT: Disruption in mucins (MUCs) is involved in cancer development and metastasis and is thus used as a biomarker. Non‑small cell lung carcinoma (NSCLC) is characterized by heterogeneous genetic and epigenetic alterations. Lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC) are the two primary subtypes of NSCLC that require different therapeutic interventions. Here, we report distinct expression and epigenetic alterations in mucin 22 (MUC22), a new MUC family member, in LUSC vs. LUAD. In lung cancer cell lines and tissues, MUC22 was downregulated in LUSC (MUC22^Low) but upregulated in LUAD (MUC22^High) with co‑expression of MUC21. The aberrant expression of MUC22 was inversely correlated with its promoter hypermethylation i

SUBMITTER: Lin S 

PROVIDER: S-EPMC8020203 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature